The U.S. Food and Drug Administration (FDA) has issued an approval (status “AP”) for ANDA078849, an abbreviated new drug application submitted by Ranbaxy Labs Ltd.
The application covers two oral ramipril capsule products – 5 mg (product number 001) and 10 mg (product number 002). Both are listed with a marketing status of “Discontinued.” The original submission was filed on 2009‑03‑06.
Cập nhật pháp chế31 thg 8, 2026•1 phút đọc
FDA Approves Ranbaxy Ramipril Capsules (ANDA078849)
FDA approves ANDA078849 submitted by Ranbaxy Labs Ltd for oral ramipril 5 mg and 10 mg capsules, both listed as discontinued.
Tổng hợp bởi đội ngũ PharmaCountry · Nguồn: FDA.gov
Đánh giá
(0)
(0)
(0)
(0)
(0)
Bài viết khác
Xem tất cả bài viếtNghiên cứu & Báo cáo
Global Finished Dosage Manufacturing Landscape 2026
5 thg 10, 2026
Cập nhật pháp chếKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 thg 9, 2026
Phân tíchPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 thg 9, 2026
Để lại đánh giá